2003PubMedRequires access

[Factor Xa inhibitory assay to detect plasma heparin concentrations during and after cardiopulmonary bypass].

Lanlan Wang, Lixin Li, Yingkang Shi, Qiang Fang

Open publisher page 2 citations

Abstract

OBJECTIVE: For establishment and application of Xa Factor Inhibitory Assay to detect plasma heparin concentrations during and after cardiopulmonary bypass (CPB) and to evaluate the treatment with low-dose protamine reversal of heparin. METHODS: Venous blood samples were drawn from 25 patients with rheumatic valvular disease undergoing valvular replacement at different points (before CPB, after 5 min of heparinization, at termination of CPB, after 10 min, 1 hr and 5 hr of protamine reversal of heparin), and the plasma heparin concentrations were detected. RESULTS: The mean of plasma heparin concentration was the highest (13.16 U/ml) after 5 min of heparinization. At termination of CPB, it decreased (11.06 U/ml) and was significantly different from the concentrations at other points (P < 0.05). After 10 min of low-dose protamine reversal of heparin, the heparin concentration (0.45 U/ml) decreased to the same as that before CPB and continued to be stable at 1 hr and 5 hr; there was no significant difference in heparin concentration between these 4 points (P > 0.05). The highest batch CV in standard curves was 11.65%; the lowest was 0.37%. CONCLUSION: Factor Xa Inhibitory Assay is of good accuracy and repetition. The results from its clinical application demonstrated that the plasma heparin concentration of the patient at termination of CPB should be used for reference in determining the dose level of protamine for that every patient subjected to CPB.

About this research paper

What this paper is about

OBJECTIVE: For establishment and application of Xa Factor Inhibitory Assay to detect plasma heparin concentrations during and after cardiopulmonary bypass (CPB) and to evaluate the treatment with low-dose protamine reversal of heparin. METHODS: Venous blood samples were drawn from 25 patients with rheumatic valvular disease undergoing valvular replacement at different points (before CPB, after 5 min of heparinization, at termination of CPB, after 10 min, 1 hr and 5 hr of protamine reversal of heparin), and the plasma heparin concentrations were detected. RESULTS: The mean of plasma heparin concentration was the highest (13.16 U/ml) after 5 min of heparinization. At termination of CPB, it decreased (11.06 U/ml) and was significantly different from the concentrations at other points (P < 0.05). After 10 min of low-dose protamine reversal of heparin, the heparin concentration (0.45 U/ml) decreased to the same as that before CPB and continued to be stable at 1 hr and 5 hr; there was no significant difference in heparin concentration between these 4 points (P > 0.05). The highest batch CV in standard curves was 11.65%; the lowest was 0.37%. CONCLUSION: Factor Xa Inhibitory Assay is of good accuracy and repetition. The results from its clinical application demonstrated that the plasma heparin concentration of the patient at termination of CPB should be used for reference in determining the dose level of protamine for that every patient subjected to CPB.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: For establishment and application of Xa Factor Inhibitory Assay to detect plasma heparin concentrations during and after cardiopulmonary bypass (CPB) and to evaluate the treatment with low-dose protamine reversal of heparin. METHODS: Venous blood samples were drawn from 25 patients with rheumatic valvular disease undergoing valvular replacement at different points (before CPB, after 5 min of heparinization, at termination of CPB, after 10 min, 1 hr and 5 hr of protamine reversal of heparin), and the plasma heparin concentrations were detected. RESULTS: The mean of plasma heparin concentration was the highest (13.16 U/ml) after 5 min of heparinization. At termination of CPB, it decreased (11.06 U/ml) and was significantly different from the concentrations at other points (P < 0.05). After 10 min of low-dose protamine reversal of heparin, the heparin concentration (0.45 U/ml) decreased to the same as that before CPB and continued to be stable at 1 hr and 5 hr; there was no significant difference in heparin concentration between these 4 points (P > 0.05). The highest batch CV in standard curves was 11.65%; the lowest was 0.37%. CONCLUSION: Factor Xa Inhibitory Assay is of good accuracy and repetition. The results from its clinical application demonstrated that the plasma heparin concentration of the patient at termination of CPB should be used for reference in determining the dose level of protamine for that every patient subjected to CPB.

Key concepts: Cardiopulmonary bypass, Heparin, Protamine, Anesthesia, Protamine sulfate, Medicine, Chemistry, Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
[Factor Xa inhibitory assay to detect plasma heparin concentrations during and after cardiopulmonary bypass]. — Research Paper | ScholarLens